- active not recruitingPHASE3
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
This study is looking at the safety of a new patch treatment, called Viaskin Peanut Patch (DBV712), for peanut allergy in very young children (1 to 3 years old). It aims to see if the patch is safe over six months, with some children receiving the patch and others a dummy patch.
United States · Australia · Canada - authorisedPhase I and Phase II (Integrated)- First administration to humans
A multicenter double-blind, randomized, placebo-controlled phase I/II study to determine the safety, tolerability, potential efficacy and dose finding of INP20, an oral formulation for treatment of immunotherapy in peanut-allergic patients.
This study is testing a new oral medication, INP20, for people with peanut allergies. It aims to see if it's safe, how well people tolerate it, to find the right dose, and if it helps reduce allergic reactions to peanuts.
Spain - active not recruitingNA
Using Commonly Available Food Products To Treat Food Allergy
This study explores using everyday foods to treat peanut and cow's milk allergies in young people. It aims to make allergic individuals less sensitive to these foods, hoping to reduce severe reactions. Researchers will also look at how cost-effective this treatment is.
United Kingdom - not yet recruitingPHASE2
Comparing Standard and Autoclaved Peanut Oral Immunotherapy in People With Peanut Allergy
This study looks at new ways to treat peanut allergy in 4- to 30-year-olds. We're comparing two types of peanuts – standard and specially heated ones – to see which is safer and works better to help people tolerate peanuts.
Canada - recruitingNA
Investigating Modified Protocols of Oral Immunotherapy to Validate Efficacy and Safety
This study looks into safer ways to treat severe food allergies like peanut, milk, and egg. It's testing if using very small amounts of allergens or cooked versions can help people become less allergic with fewer side effects.
Canada - ongoing, recruitingTherapeutic confirmatory (Phase III)
EPITOPE Open-label Extension Study to Evaluate the Long-term Clinical Benefit and Safety of DBV712 in Peanut-Allergic Children (EPOPEX)
This study, called EPOPEX, is looking at how well a special skin patch, Viaskin Peanut, works over a long time to help children with peanut allergy. It checks if the patch continues to reduce their allergic reactions and if it's safe to use for up to three years.
Germany · Netherlands